Higher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease.

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorSpósito, Pollyanna Álvaro-
Autor(es): dc.creatorMazzeti, Ana Lia-
Autor(es): dc.creatorCastro, Kelly Christyne Miranda Pereira de-
Autor(es): dc.creatorMendes, Priscila Fagundes-
Autor(es): dc.creatorUrbina, Julio Alberto-
Autor(es): dc.creatorBahia, Maria Terezinha-
Autor(es): dc.creatorMosqueira, Vanessa Carla Furtado-
Data de aceite: dc.date.accessioned2025-08-21T15:17:39Z-
Data de disponibilização: dc.date.available2025-08-21T15:17:39Z-
Data de envio: dc.date.issued2023-05-03-
Data de envio: dc.date.issued2023-05-03-
Data de envio: dc.date.issued2020-
Fonte completa do material: dc.identifierhttp://www.repositorio.ufop.br/jspui/handle/123456789/16511-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0014489421000795?via%3Dihub-
Fonte completa do material: dc.identifierhttps://doi.org/10.1016/j.exppara.2021.108142-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1009482-
Descrição: dc.descriptionWe investigated the in vitro activity and selectivity, and in vivo efficacy of ravuconazole (RAV) in self- nanoemulsifying delivery system (SNEDDS) against Trypanosoma cruzi. Novel formulations of this poorly solu- ble C14-α-demethylase inhibitor may improve its efficacy in the experimental treatment. In vitro activity was determined in infected cardiomyocytes and efficacy in vivo evaluated in terms of parasitological cure induced in Y and Colombian strains of T. cruzi-infected mice. In vitro RAV-SNEDDS exhibited significantly higher potency of 1.9-fold at the IC50 level and 2-fold at IC90 level than free-RAV. No difference in activity with Colombian strain was observed in vitro. Oral treatment with a daily dose of 20 mg/kg for 30 days resulted in 70% of cure for RAV- SNEDDS versus 40% for free-RAV and 50% for 100 mg/kg benznidazole in acute infection (T. cruzi Y strain). Long-term treatment efficacy (40 days) was able to cure 100% of Y strain-infected animals with both RAV preparations. Longer treatment time was also efficient to increase the cure rate with benznidazole (Y and Colombian strains). RAV-SNEDDS shows greater efficacy in a shorter time treatment regimen, it is safe and could be a promising formulation to be evaluated in other pre-clinical models to treat T. cruzi and fungi infections.-
Formato: dc.formatapplication/pdf-
Idioma: dc.languageen-
Direitos: dc.rightsrestrito-
Palavras-chave: dc.subjectY strain-
Palavras-chave: dc.subjectTrypanosoma cruzi-
Palavras-chave: dc.subjectRavuconazole-
Palavras-chave: dc.subjectSelf-nanoemulsifying drug delivery system-
Palavras-chave: dc.subjectEfficacy-
Título: dc.titleHigher oral efficacy of ravuconazole in self-nanoemulsifying systems in shorter treatment in experimental chagas disease.-
Aparece nas coleções:Repositório Institucional - UFOP

Não existem arquivos associados a este item.